Hansoh Pharma grants Roche an exclusive license to novel CDH17-targeting ADC HS-20110

CAR-T Digest - August 2020

17 October 2025: Hansoh Pharma grants Roche an exclusive license to novel CDH17-targeting ADC HS-20110

Hansoh Pharma has granted Roche an exclusive worldwide license (excluding Mainland China, Hong Kong, Macau, and Taiwan) to its investigational CDH17-targeting ADC, HS-20110, for clinical development and commercialization
HS-20110 utilizes a clinically validated topoisomerase inhibitor (TOPOi) payload and has shown early clinical activity in solid tumors, including colorectal cancer (CRC)
Under the agreement, Hansoh Pharma will receive an upfront payment of US $80 million, along with potential development, regulatory, and commercialization milestone payments
Hansoh Pharma is also entitled to royalties on future product sales, reflecting the long-term commercial potential of HS-20110
The partnership with Roche is expected to accelerate the clinical development and potential approval of HS-20110, supporting Hansoh Pharma’s mission to deliver transformative cancer treatments globally